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Methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSIs) are associated with significant morbidity and
mortality. MSSA BSIs can rapidly disseminate, resulting in deep-seated infections, prolonged durations of bacteremia, and further
metastases. Recently, cefazolin and ertapenem combination therapy has emerged as a potential therapeutic strategy to sterilize the
blood in patients with persistent MSSA bacteremia. Here, we present a patient with COVID-19 pneumonia and concomitant
MSSA BSI achieving blood culture sterilization within 24 hours of cefazolin and ertapenem combination therapy initiation
following 11 days of positive blood cultures.

1. Introduction
Staphylococcus aureus is a leading cause of bloodstream infections (BSIs), with an annual incidence in the United States
of approximately 30 cases per 100,000 person-years [1].
S. aureus BSI is associated with high morbidity and mortality,
with 30-day all-cause mortality rates ranging from 20 to 30%
[2, 3]. In recent years, MSSA has once again emerged as the
predominant cause of staphylococcal bacteremia [4]. Thus,
optimizing treatment strategies for MSSA BSI is paramount.
The treatment of choice for MSSA BSI is source control
along with an antistaphylococcal penicillin, such as oxacillin or
nafcillin or cefazolin [5]. Persistent bacteremia, defined anywhere from 2 to 7 days of positive blood cultures despite appropriate antibiotic therapy, is associated with worse outcomes
and higher mortality compared to bacteremias that clear rapidly
[6, 7]. Unfortunately, modifications to antibacterial therapy,
including the addition of rifampin [8] and daptomycin [9], have
not proven beneficial in patients with MSSA BSI. The addition of
gentamicin has been used historically but is no longer recommended due to an unacceptable risk of nephrotoxicity when
combined with antistaphylococcal penicillins [5].

Recently, combination therapy with cefazolin and
ertapenem has emerged as a possible rescue therapy in
patients with persistent MSSA BSI. The combination
demonstrated synergy both in vitro and in vivo in a murine
skin infection model [10]. In a small case series, combination
therapy was found to sterilize blood cultures within 24 hours
of initiation in 8 of 9 patients with daily blood culture
samples [11]. In another case report of a neonate with eight
days of positive blood cultures, escalating to cefazolin and
ertapenem preceded negative blood cultures 30 hours later
[12]. More data, however, about clinical outcomes are
needed. Here, we describe a case in which blood culture
sterilization was observed within 24 hours of initiation of
cefazolin and ertapenem combination therapy after 11 days
of persistent bacteremia on oxacillin in a patient with MSSA
BSI and COVID-19.

2. Case Description
A 45-year-old male with a past medical history significant
for obstructive sleep apnea, congenital club foot status post
corrective surgery years prior, and recently diagnosed
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COVID-19 (10 days prior to admission) presented to the
emergency department with increasing weakness, fatigue,
and loss of appetite. The patient got tested for COVID-19
after his partner developed respiratory symptoms. Respiratory symptoms at home included cough, shortness of
breath, and fevers. The patient also reported using his
continuous positive airway pressure machine during the day
for increased dyspnea. Additionally, he reported progressive
right ankle pain and redness over the last week. On physical
exam, the right ankle was warm and erythematous without
gross eﬀusion and was tender to palpation and passive range
of motion. Initial vital signs were remarkable for a respiratory rate of 28 breaths/minute, heart rate of 116 beats/
minute, blood pressure of 184/96 mm·Hg, and a body mass
index of 40 kg/m2. Complete metabolic panel revealed an
elevated glucose of 462 mg/dL, blood urea nitrogen of 80 mg/dL,
and serum creatinine of 5.40 mg/dL (estimated creatinine
clearance 23 ml/min). Additional labs were remarkable
for HgA1c of 7.2%, NT-proBNP of 867 pg/mL, CRP of
329.3 mg/dL, ESR of 103 mm/hr, lactate of 2.7 mmol/L, and a
D-dimer of 4623 mcg/mL. Blood and urine cultures were
sent. Chest X-ray showed bilateral patchy airspace and interstitial opacities, predominantly involving the periphery of
the right lung. Right ankle/foot X-ray showed ﬁndings
consistent with prior congenital foot surgery without osseous erosions or fractures. He received 1 L lactated ringers,
5 units of lispro, and a dose of intravenous vancomycin
1750 mg before transfer to the medical intensive care unit
(MICU) for BiPAP.
Complete details of the hospital course are provided in
Table 1. The patient was initially started on intravenous
dexamethasone and remdesivir in the MICU. Antimicrobial
therapy was changed to oxacillin on day 2 following the
detection of MSSA in initial blood cultures via Verigene
Blood Culture Nucleic Acid Test. Infectious disease was
consulted the following day in accordance with institutional
practice for all patients with staphylococcal BSIs. An MRI
performed on the right ankle revealed diﬀuse skin thickening and edema of foot and ankle without evidence of OM,
large complex tibiotalar joint eﬀusion with synovitis, and
abscess along the ﬂexor hallucis longus muscle (Figure 1),
which was urgently debrided in the operating room. The
following day, the patient was weaned from BiPAP back to
CPAP at night only.
Despite initial source control and appropriate antimicrobial therapy, blood cultures remained positive. Echocardiographic imaging on days 2 and 7 did not reveal any
valvular vegetations; yet, the patient remained persistently
bacteremic despite therapy with intravenous oxacillin. On
day 9 of admission, the patient was escalated to intravenous
cefazolin and ertapenem combination therapy and dexamethasone was stopped with the completion of 10 doses. On
the same day, an MRI spine revealed discitis/osteomyelitis of
the cervical spine with associated epidural abscess (Figure 2).
The patient was taken for urgent debridement and C3 to C4
cervical fusion. Intraoperative spinal cultures grew MSSA.
Repeat blood cultures within 24 hours of administration of
cefazolin and ertapenem combination therapy ﬁnalized
without growth. Follow-up cultures remained sterile
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through hospital discharge on day 19. The patient was
discharged to a long-term acute care facility to complete 6
weeks of intravenous cefazolin and ertapenem from the ﬁrst
negative blood culture.

3. Discussion
MSSA bacteremia is a common BSI associated with signiﬁcant morbidity and mortality [2, 3]. Eﬀective management includes source control and treatment with
antistaphylococcal penicillin or cefazolin. Limited therapeutic options exist for recalcitrant MSSA BSIs not
responding to standard therapy and source control.
Here, we report on a patient with newly diagnosed diabetes mellitus, COVID-19 pneumonia, and concomitant
MSSA BSI not responding to the standard of care therapy
with oxacillin and initial source control procedures. Following more than 10 days of persistent bacteremia, blood
cultures were sterilized within 24 hours of administration of
cefazolin and ertapenem combination therapy.
Cefazolin and ertapenem bind to diﬀerent penicillinbinding proteins (PBPs), with ertapenem selectively targeting
PBP1 and cefazolin predominantly binding to PBP2. [13–15]
Such complementary binding aﬃnities provide the theoretical
pharmacodynamic foundation for utilizing these two agents
in combination. A recent case series highlights the potential
utility of cefazolin and ertapenem in combination as salvage
therapy for persistent MSSA BSIs [11]. In this series, 8 of 11
patients achieved negative blood cultures within 24 hours of
initiation of salvage therapy. Most patients in this series had
deep-seated infections, including 6 with endocarditis and 2
with spinal osteomyelitis and epidural abscesses. Additionally, the authors noted synergy when testing the combination
in vitro and in a rat model of endocarditis [11]. While the
duration of S. aureus bacteremia has not been associated with
90-day mortality, it has been associated with other signiﬁcant
complications. These include new metastatic foci of infection
(often requiring surgical interventions), relapse of bacteremia,
longer hospital stay, and complications due to longer hospital
stay [7, 16]. Together, these serve as a rationale for salvage
therapy with combination antimicrobials in recalcitrant
bacteremia.
Regarding the management of the patient’s COVID-19
pneumonia, our patient initially received intravenous
dexamethasone and remdesivir; however, the latter was held
following the administration of a loading dose given the
patient’s acute renal failure. Dexamethasone was continued
for a complete 10-day course in accordance with clinical
treatment guidelines [17]; however, new initiation of corticosteroids in patients with staphylococcal BSIs without
concomitant shock has been associated with increased allcause mortality at 28 and 90 days [18]. These data highlight
the need to critically weigh the risks and beneﬁts of continued dexamethasone therapy in the setting of secondary
infections in patients with COVID-19.
One ﬁnal consideration is the timing of source control
relative to the imitation of cefazolin and ertapenem combination therapy. As a case report, we cannot be certain of
the causal link between the antibiotic change and the

Case Reports in Infectious Diseases

3
Table 1: Summary of hospital course.

Day Tmax WBC SCr
ED

40.5

8.0

Cultures
Antimicrobials
Imaging
Bcx: 2/2 MSSA; TTP 8.3 Vancomycin 1750 mg X-ray R foot/ankle, X-ray chest
5.10
hours
IV × 1
per HPI

1

37.9

8.1

4.44

2

37.3

8.7

4.19

3

37.3

7.6

2.53

4

38.5

5.3

2.12

5

38.8

5.7

1.82

6

38.9

6.2

1.57

7

38.7

4.2

1.47

8

37.9

7.1

1.51

9

37.7

—

—

10

37.2

7.1

1.39

11

36.9

6.0

1.23

12

37.2

4.1

1.10

Comments
—

Ortho attempted aspiration
Cefepime 2 g IV q24 h,
CT chest PE protocol: no PE, of R ankle—dry tap. Oxacillin
linezolid 600 mg IV
Bcx: 2/2 MSSA
possible septic emboli and L IJ 2 g IV q4 h started following
q12 h, remdesivir
thrombophlebitis
detection of MSSA in ED
200 mg IV × 1
blood cultures.
Panorex: periapical abscesses
Remdesivir stopped by MICU
Bcx: 2/2 MSSA
at #30. Duplex LEs: No DVTs.
due to AKI. ID consulted.
TTE: No vegetations
MRI R ankle (Figure 1): diﬀuse
skin thickening and edema of OR with ortho s/p R ankle
Ankle tissue culture: 5/5
foot and ankle w/o evidence of I&D and arthrotomy; R leg
MSSA; tracheal aspirate:
OM; large complex tibiotalar
FHL abscess I&D. Dental
Oxacillin 2 g IV q4 h
MSSA
joint eﬀusion w/synovitis and
consulted.
abscess along the FHL muscle
Bcx: 2/2 MSSA
X-ray chest: mild interval
improvement in b/l interstitial Weaned oﬀ BiPAP; CPAP at
night only. Tooth #30
airspace opacities c/w
Bcx: 2/2 MSSA
extracted.
COVID-19 pneumonia, septic
pulmonary emboli
CT CAP w/contrast: cavitating
pulmonary septic emboli, ﬂuid Ceftriaxone added by ICU
collection around L SC joint c/
team for Gram-negative
Bcx: 2/2 MSSA;
f early septic arthritis,
coverage given fever and
COVID-19 RNA
Oxacillin 2 g IV q4 h,
phlegmon within R iliacus
tachycardia; X-rays looking
nasopharyngeal swab: ceftriaxone 2 g IV × 1
muscle. X-ray L knee/ankle: L
for prior hardware; no
positive
knee medial osteoarthritis, L
surgical indication for SC
foot cellulitis, and acute on
joint per thoracic surgery.
chronic achilles tendinopathy
Tee: no vegetations noted
MSK IR consulted for iliacus
Bcx: 2/2 MSSA
muscle phlegmon.
Oxacillin 2 g IV q4 h,
Bcx: 1/1 MSSA
X-ray L shoulder/R knee: no
ceftriaxone 1 g IV
Transferred to ﬂoor.
evidence of OM or septic
q24 h
Bcx: 1/1 MSSA;
Ceftriaxone discontinued. ID
arthritis. MRI L knee/ankle/
TTP � 13.6 hours
recommend to change
foot: severe L knee chondrosis,
Bcx: 2/2 MSSA;
oxacillin to cefazolin plus
small L knee joint eﬀusions, L
TTP � 22.5 hrs; L foot
ertapenem. Last dose
ankle and foot cellulitis, small
aspiration: MSSA;
dexamethasone given. Ortho
nonspeciﬁc collection
cervical spine wound:
spine consulted.
extending dorsally from
MSSA
rd
between the base of the L 3
and 4th metatarsal, likely
represents extension of
Cefazolin 2 g IV q8 h,
adventitial bursitis. US lower
ertapenem 1 g IV
back: loculated ﬂuid collection
L 3rd/4th metatarsal
q24 h
deep and posterior in pelvis.
aspiration; OR for cervical
Bcx: 2/2 no growth
MRI brain/spine (Figure 2):
fusion/epidural abscess
C3-C4 discitis/OM w/epidural drainage with ortho spine.
abscess, no intracranial
abnormality. CT spine: C3-C4
discitis/OM w/epidural
abscess
Bcx: 2/2 no growth
—
—

Bcx, blood culture(s); TTP, time-to-positivity; FHL, ﬂexor hallucis longus; SC, sternoclavicular; OM, osteomyelitis.

cessation of bacteremia, but the temporal proximity does
raise this as a possibility. In addition, while an undrained
epidural abscess could explain persistent fevers and symptoms, undrained collections are rarely the cause of continuous bacteremia (hence, our clinical use of continuous

bacteremia as the sine qua non of endovascular infection). In
total, this case suggests to us the possibility of an eﬀect, and
one worth reporting as a case study, in order to pique the
interest of other clinicians or to contribute eventually to a
case series, before undertaking a more rigorous study design.
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Figure 1: MRI of right ankle showing large complex tibiotalar joint
eﬀusion with synovitis and associated ﬂuid collection along the
ﬂexor hallucis longus muscle belly (day 3 of hospitalization).

Figure 2: MRI of spine with and without contrast showing C3-C4
discitis-osteomyelitis (black arrow), with associated epidural abscess (day 9 of hospitalization).

4. Conclusion
Cefazolin and ertapenem combination therapy resulted in
successful sterilization of blood cultures within 24 hours of
administration in a patient previously bacteremic for more
than 10 days despite optimal pharmacotherapy. The patient’s
MSSA BSI may have been aggravated by continued administration of dexamethasone for COVID-19. Clinicians
should consider weighing the risks and beneﬁts of dexamethasone administration in the setting of concomitant
infections.
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